[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] MOURAD M,JETMORE T,JATEGAONKAR A A,et al.Epidemiological trends of head and neck cancer in the United States:A SEER population study[J].J Oral Maxillofac Surg,2017,75(12):2562-2572.
[3] THOMPSON L,FRANCHI A.New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors:nasal cavity,paranasal sinuses and skull base[J].Virchows Arch,2018,472(3):315-330.
[4] MUZAFFAR J,BARI S,KIRTANE K,et al.Recent advances and future directions in clinical management of head and neck squamous cell carcinoma[J].Cancers,2021,13(2):338.
[5] ANAND A K,AGARWAL J P,D'CRUZ A,et al.Evolving multidisciplinary treatment of squamous cell carcinoma of the head and neck in India[J].Cancer Treat Res Commun,2021,26:100269.
[6] 钱程程,袁海花,姜斌.头颈部鳞癌预后相关肿瘤标志物的研究现状[J].现代肿瘤医学,2021,29(5):888-892.
[7] MAJCHRZAK-GORECKA M,MAJEWSKI P,GRYGIER B,et al.Secretory leukocyte protease inhibitor (SLPI),a multifunctional protein in the host defense response[J].Cytokine Growth Factor Rev,2016,28:79-93.
[8] NUGTEREN S,SAMSOM J N.Secretory leukocyte protease inhibitor (SLPI) in mucosal tissues:protects against inflammation,but promotes cancer[J].Cytokine Growth Factor Rev,2021,59:22-35.
[9] BOUCHARD D,MORISSET D,BOURBONNAIS Y,et al.Proteins with whey-acidic-protein motifs and cancer[J].Lancet Oncol,2006,7(2):167-174.
[10] DRANNIK A G,HENRICK B M,ROSENTHAL K L.War and peace between WAP and HIV:role of SLPI,trappin-2,elafin and ps20 in susceptibility to HIV infection[J].Biochem Soc Trans,2011,39(5):1427-1432.
[11] WOODHAM A W,DA SILVA D M,SKEATE J G,et al.The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection[J].PLoS One,2012,7(8):e43519.
[12] FAKIOGLU E,WILSON S S,MESQUITA P M M,et al.Herpes simplex virus downregulates secretory leukocyte protease inhibitor:a novel immune evasion mechanism[J].J Virol,2008,82(19):9337-9344.
[13] SKEATE J G,PORRAS T B,WOODHAM A W,et al.Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection[J].J Gen Virol,2016,97(2):422-434.
[14] TSE K,WU C,HSUEH C,et al.The relationship between secretory leukocyte protease inhibitor expression and epstein-barr virus status among patients with nasopharyngeal carcinoma[J].Anticancer Res,2012,32(4):1299-1307.
[15] WAHL S M,ASHCROFT G S,LEI K,et al.Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing[J].Nat Med,2000,6(10):1147-1153.
[16] HE Z,BATEMAN A.Progranulin (granulin-epithelin precursor,PC-cell-derived growth factor,acrogranin) mediates tissue repair and tumorigenesis[J].J Mol Med Berl,2003,81(10):600-612.
[17] ZHANG D,SIMMEN R C M,MICHEL F J,et al.Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes[J].J Biol Chem,2002,277(33):29999-30009.
[18] JETHWA A R,KHARIWALA S S.Tobacco-related carcinogenesis in head and neck cancer[J].Cancer Metastasis Rev,2017,36(3):411-423.
[19] QUABIUS E S,MÖLLER P,HAAG J,et al.The role of the antileukoprotease SLPI in smoking-induced human papillomavirus-independent head and neck squamous cell carcinomas[J].Int J Cancer,2014,134(6):1323-1334.
[20] QUABIUS E S,BÖGERSHAUSEN B,GETZIN L,et al.SLPI and AnxA2 expression in neoplasm-free palatine tonsils is associated with smoking habit of individuals[J].Mol Clin Oncol,2017,7(3):427-434.
[21] QUABIUS E S,GÖRÖGH T,FISCHER G S,et al.The antileukoprotease secretory leukocyte protease inhibitor (SLPI) and its role in the prevention of HPV-infections in head and neck squamous cell carcinoma[J].Cancer Lett,2015,357(1):339-345.
[22] CHOW L.Head and neck cancer[J].N Engl J Med,2020,382(1):60-72.
[23] DICKEY B L,SIRAK B,MARTIN-GOMEZ L,et al.Oral secretory leukocyte protease inhibitor (SLPI):associations with oropharyngeal cancer and treatment outcome[J].PLoS One,2021,16(7):e254161.
[24] ZHANG Q,CHEN Y,HU S Q,et al.A HPV16-related prognostic indicator for head and neck squamous cell carcinoma[J].Ann Transl Med,2020,8(22):1492.
[25] JIN Y,LI Y,WANG X,et al.Secretory leukocyte protease inhibitor suppresses HPV E6-expressing HNSCC progression by mediating NF-κB and Akt pathways[J].Cancer Cell Int,2019,19(1):220.
[26] CORDES C,HASLER R,WERNER C,et al.The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma[J].Int J Oncol,2011,39(1):185-191.
[27] WEN J,NIKITAKIS N G,CHAISUPARAT R,et al.Secretory leukocyte protease inhibitor (slpi) expression and tumor invasion in oral squamous cell carcinoma[J].Am J Pathol,2011,178(6):2866-2878.
[28] QIAN B,POLLARD J W.Macrophage diversity enhances tumor progression and metastasis[J].Cell,2010,141(1):39-51.
[29] WESTIN U,NYSTROM M,LJUNGCRANTZ I,et al.The presence of elafin,SLPI,IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation[J].Mediators Inflamm,2002,11(1):7-12.
[30] NOORLAG R,VAN DER GROEP P,LEUSINK F K,et al.Nodal metastasis and survival in oral cancer:association with protein expression of SLPI,not with LCN2,TACSTD2,or THBS2[J].Head Neck,2015,37(8):1130-1136.
[31] KASALA D,HONG J,YUN C.Overcoming the barriers to optimization of adenovirus delivery using biomaterials:current status and future perspective[J].J Control Release,2021,332:285-300.
[32] CHEN J,YANG B,ZHANG S,et al.Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma[J].Cancer Gene Ther,2012,19(5):328-335.
[33] FASANO M,DELLA CORTE C M,VISCARDI G,et al.Head and neck cancer:the role of anti-EGFR agents in the era of immunotherapy[J].Ther Adv Med Oncol,2021,13:386356445.
[34] CHEN J,ZHANG S,LIN Y,et al.Antitumor efficacy of SLPI promoter-controlled expression of artificial microRNA targeting EGFR in a squamous cell carcinoma cell line[J].Pathol Oncol Res,2017,23(4):829-835. |
